Your Article Summary
See Latest ArticlesExperience of Mycophenolate Mofetil in 10 Patients With Autoimmune-Related Interstitial Lung Disease Demonstrates Promising Effects
The American Journal of the Medical Sciences, 06/11/09
Saketkoo LA et al. - MMF is safe, well tolerated, and allows reduction or discontinuation of prednisone without worsening of symptoms or objective progression of disease. MMF is less toxic and its targeted antifibrotic properties make it a potentially more effective agent than CYC that may supplant it as a first-line agent or provide sensible post-CYC maintenance or synergistic strategy in the treatment of CTD-ILD.
Related Articles
Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts
Arthritis & Rheumatism, 11/11/09
Relevance Score: 69%
Lung cancer: a biologically different disease in women?
Women's Health, 10/30/09
Relevance Score: 68%
Radiochemotherapy in small-cell lung cancer
Expert Review of Anticancer Therapy, 10/20/09
Relevance Score: 68%
Nocturnal hypoxia and sleep disturbances in cystic fibrosis
Pediatric Pulmonology, 10/14/09
Relevance Score: 68%
Risk of Acute Exacerbation After Video-assisted Thoracoscopic Lung Biopsy for Interstitial Lung Disease
Journal of Bronchology, 10/14/09
Relevance Score: 68%
Today in Restrictive Lung Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Pirfenidone in idiopathic pulmonary fibrosis
European Respiratory Journal , 12/10/09
Predictors of Body Mass Index in Patients With Moderate to Severe Emphysema
COPD: Journal of Chronic Obstructive Pulmonary Disease, 12/09/09
Prevalence and clinical correlates of bronchoreversibility in severe emphysema
European Respiratory Journal , 12/08/09